ArticleACS medicinal chemistry letters2020
Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment.
Article in ACS medicinal chemistry letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04859244 (First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of Orally Administered GS-441524 in a Healthy Human Volunteer), which is not on this map. Cited by 112 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of Orally Administered GS-441524 in a Healthy Human Volunteer
Who cites it
112 citing papers in PubMed, 1 synthesis or guideline pooled it, 169 citations in OpenAlex.
- Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis.European journal of pharmacology · 2021Pooled it
- SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir.The Journal of infectious diseases · 2024Trial
- A mouse-adapted Yezo virus model for antiviral testing in immunocompetent mice.Nature communications · 2026Article
- Screening assay to monitor mono-ADP-ribosylhydrolase activity of viral macrodomains in cells.Communications biology · 2026Article
- Article
- Optimizing drug combinations to resurrect the potency of failed antibody therapy against emerging COVID-19 variants using IDentif.AI.Frontiers in digital health · 2026Article
- Analysis of risk factors, clinical data, treatment outcomes for cats with feline infectious peritonitis using GS-441524 (2020-2024).Scientific reports · 2025Article
- Clinical therapeutics in feline medicine: updates for old and new drugs.Journal of feline medicine and surgery · 2025Review
- Article
- Exploring the Therapeutic Potential ofJournal of microbiology and biotechnology · 2025Article
- Remdesivir-induced severe hypoglycemia in an elderly man without diabetes: a case report.Journal of pharmaceutical health care and sciences · 2025Article
- Article
- Pharmacokinetic simulations for remdesivir and its metabolites in healthy subjects and patients with renal impairment.Frontiers in pharmacology · 2025Article
- A robust mouse model of HPIV-3 infection and efficacy of GS-441524 against virus-induced lung pathology.Nature communications · 2024Article
- Clinical pharmacodynamics of obeldesivir versus remdesivir.Antimicrobial agents and chemotherapy · 2024Article
- Antiviral drug recognition and elevator-type transport motions of CNT3.Nature chemical biology · 2024Article
- Remdesivir treatment does not reduce viral titers in patients with COVID-19.Antimicrobial agents and chemotherapy · 2024Article
- GS-441524-Diphosphate-Ribose Derivatives as Nanomolar Binders and Fluorescence Polarization Tracers for SARS-CoV-2 and Other Viral Macrodomains.ACS chemical biology · 2024Article
- Differential Bioactivation Profiles of Different GS-441524 Prodrugs in Cell and Mouse Models: ProTide Prodrugs with High Cell Permeability and Susceptibility to Cathepsin A Are More Efficient in Delivering Antiviral Active Metabolites to the Lung.Journal of medicinal chemistry · 2024Article
- Potent Dual Polymerase/Exonuclease Inhibitory Activities of Antioxidant Aminothiadiazoles Against the COVID-19 Omicron Virus: A Promising In Silico/In Vitro Repositioning Research Study.Molecular biotechnology · 2024Article
52 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While remdesivir has garnered much hope for its moderate anti-Covid-19 effects, its parent nucleoside, GS-441524, has been overlooked. Pharmacokinetic analysis of remdesivir evidences premature serum hydrolysis to GS-441524; GS-441524 is the predominant metabolite reaching the lungs. With its synthetic simplicity and
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.